ERBB2 and breast cancer: In non-surgical area, improvements in multimodal therapy, including advances in modern radiotherapy technology, optimization of chemotherapy, and anti-HER2 therapy regimens, novel endocrine agents, and target drugs, as well as clinical utility of immunotherapy, could further diminish breast cancer mortality and contribute to increase chances for cure in 70%–80% patients with early breast cancer (18, 19).